Future work could focus upon performing longer term studies with EPO and HIF‐PHDi to identify whether FGF23 suppression is indirect through tissue–tissue interactions, or whether iron/oxygen content directly reduces anemia‐driven FGF23 production via suppression of HIF1‐2α transcriptional activity in osteocytes. The gene discussed is EPO; the disease is anemia.